Jeta Molecular

JETA Molecular is a private, commercial-stage diagnostics company specializing in post-transplant monitoring. Its core technology platform leverages quantitative PCR (qPCR) and digital PCR (dPCR) to deliver highly sensitive chimerism and donor-derived cell-free DNA (dd-cfDNA) tests for hematopoietic stem cell transplant (HSCT) and solid organ transplant patients. With CE-marked products already on the market, JETA is positioned to address a critical unmet need in transplantation medicine by providing tools for early intervention, potentially improving graft survival and patient quality of life. The company benefits from founder expertise and collaborations with key opinion leaders in the field.

Integrated molecular diagnostics platform based on quantitative PCR (qPCR) and digital PCR (dPCR) for chimerism and donor-derived cell-free DNA (dd-cfDNA) monitoring. Features proprietary INDEL marker panels, assay formulations, and TRACE Analysis™ software for a complete workflow from testing to data analysis and reporting.

JETA competes in niche segments of the transplant Dx market. In chimerism, it faces legacy STR-PCR methods and other qPCR/dPCR providers. In dd-cfDNA for solid organs, it competes with established players like CareDx (AlloSure) and Natera (Prospera), which have significant commercial head starts and FDA approvals in the US.